The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said on Monday.

The agreement means there will only be a 15% tariff on European imports, in exchange for $600 billion of investments in the U.S. and $750 billion purchase of U.S. energy.